Cagrilintide / Semaglutide

CagriSema - Cagrilintide / Semaglutide Combination Research Peptide

CagriSema is the co-formulated research blend of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), both developed by Novo Nordisk. It is the first once-weekly combination of a GLP-1 and an amylin analog and is the subject of the REDEFINE 1 and REDEFINE 2 Phase 3 trial programs. The two peptides act through non-overlapping signaling pathways, which is why researchers pair them in a single vial instead of running parallel single-peptide studies.

Why Pair Cagrilintide with Semaglutide

Semaglutide (the peptide behind Ozempic and Wegovy) targets the GLP-1 receptor - an incretin pathway that amplifies insulin release and slows gastric emptying. Cagrilintide targets the amylin receptor - a parallel pathway in the brainstem and hypothalamus that regulates meal size and satiety. Because the two pathways don’t overlap, the combined signal is larger than either alone, and each peptide complements what the other does not cover.

CagriSema vs Semaglutide vs Tirzepatide

These three show up in most current metabolic-research literature, so the distinction matters.

CagriSema and tirzepatide are both “dual-mechanism” compounds, but they hit different pairs: CagriSema is amylin + GLP-1, tirzepatide is GIP + GLP-1. The SURMOUNT and REDEFINE trial programs characterize each pairing independently.

Research Applications

CagriSema is used in studies examining:

• Combined amylin + GLP-1 signaling in a single administration
• Body-composition endpoints under dual-pathway stimulation
• Ad-libitum caloric-intake and satiety modeling
• Glycemic and blood-pressure markers in Phase 3 protocol replication (REDEFINE framework)
• Comparative research vs. GLP-1 monotherapy and vs. GIP/GLP-1 dual agonists

Specifications

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Cagrilintide / Semaglutide are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Cagrilintide / Semaglutide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About CagriSema Research

How is CagriSema different from semaglutide alone?

CagriSema adds cagrilintide (an amylin analog) to semaglutide. Semaglutide on its own works through a single pathway (GLP-1). CagriSema works through two non-overlapping pathways (amylin + GLP-1), which is why the combined trial endpoints are larger than semaglutide monotherapy endpoints.

Is CagriSema a GLP-1?

It contains one. CagriSema is a combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog). It is not a single peptide - it is two peptides co-formulated in one vial.

How does CagriSema compare to tirzepatide?

They are both dual-mechanism compounds but hit different receptor pairs. CagriSema pairs an amylin analog with a GLP-1 agonist. Tirzepatide is a single molecule that activates GLP-1 and GIP. A head-to-head trial (Novo Nordisk’s REDEFINE 4 / Eli Lilly’s SURMOUNT-5 framework) has been the subject of ongoing comparative research.

Is CagriSema FDA approved?

Novo Nordisk has filed for FDA approval of CagriSema (2026). At the time of writing it is not approved for any human use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is the blend stored?

Unopened vials are stored at 2-8°C and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.